Status:

UNKNOWN

Neuropathic Pain in Head and Neck Cancer

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborating Sponsors:

National Institute of Dental and Craniofacial Research (NIDCR)

Conditions:

Head and Neck Cancer

Eligibility:

All Genders

18+ years

Brief Summary

The goal of this research study is to learn more about chronic pain associated with cancer treatment.

Detailed Description

If you agree to take part in this study, you will complete the following tests and procedures at the beginning and at the end of the study (on clinic visits, typically around 3-6 months after completi...

Eligibility Criteria

Inclusion

  • Aim 1 Discovery Phase: The samples are from a large NIH-funded Genome-wide association study of squamous cell carcinoma of the head and neck (Shete; PI). A total of 2900 "case" patients and 1200 control patients were recruited for the study. In this study, we will only use cases who were: a) Newly diagnosed, untreated, histopathologically confirmed squamous cell carcinoma of the oral cavity, pharynx, or larynx; b) No previous cancers; c) Age 18 years or older; d) white Caucasian.
  • Aim 2: a) Newly diagnosed patients (have not had any prior cancer treatment) with loco-regional squamous cell carcinoma of the head and neck, b) Will receive cancer treatment at MDACC or at Ben Taub, c) Are 18 years or older, d) English or Spanish speaking; e) Able to understand the description of the study and give written informed consent; f) Will state that they will receive follow-up at MD Anderson post-treatment or at Ben Taub. This sample will also be included in the Validation Phase of Aim 1. We note that population stratification, i.e., the presence of a systematic difference in allele frequencies between subpopulations in a population possibly due to different ancestry, is an issue for genetic association studies.
  • Aim 3: Patients included in aims 1 and 2.

Exclusion

  • 1\) Exclusion for Aim 2: a) Patients with distant metastasis (Stage IVC); b. Patients participating in clinical trials/ investigational drugs for pain control. Aim 1 (discovery phase) and Aim 3 will use existing data.

Key Trial Info

Start Date :

October 15 2012

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 31 2022

Estimated Enrollment :

838 Patients enrolled

Trial Details

Trial ID

NCT01846286

Start Date

October 15 2012

End Date

December 31 2022

Last Update

May 25 2022

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Lyndon B. Johnson General Hospital (LBJ)

Houston, Texas, United States, 77026

2

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030